07:57 AM EDT, 09/09/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said Tuesday that five-year follow-up data on its phase 3 trial for Libtayo show the treatment produced a significant improvement in survival outcomes in adults with non-small cell lung cancer.

The data showed that Libtayo plus platinum-based chemotherapy demonstrated a overall survival rate of 19.4% compared to 8.8% with chemotherapy alone, the company said.

The trial evaluated the drug as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer with no EGFR, ALK, or ROS1 aberrations, Regeneron said.